Spots Global Cancer Trial Database for malignant glioma
Every month we try and update this database with for malignant glioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | NCT00859222 | Malignant Gliom... | LBH589 bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Comparative 2-D Tumor Analysis in Familial Gliomas | NCT00125710 | Malignant Gliom... | 18 Years - | AHS Cancer Control Alberta | ||
| Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study) | NCT02300532 | Malignant Gliom... | No intervention | - | Eisai Inc. | |
| Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma | NCT02039778 | Glioblastoma Malignant Gliom... Brain Tumors Anaplastic Astr... | Stem Cell Radio... | 18 Years - 70 Years | Beth Israel Medical Center | |
| Ph I Dasatinib + Erlotinib in Recurrent MG | NCT00609999 | Glioblastoma Gliosarcoma | Erlotinib and D... | 18 Years - | Duke University | |
| Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | NCT04323046 | Glioblastoma Malignant Gliom... Recurrent Gliob... Recurrent Malig... Recurrent Grade... Grade III Gliom... | Nivolumab Quality-of-Life... Questionnaire A... | 6 Months - 25 Years | University of California, San Francisco | |
| Early Palliative Care Intervention in Malignant Glioma | NCT03471546 | Malignant Gliom... | Palliative Care | 18 Years - | Duke University | |
| Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma | NCT00041587 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Mixed Oligoastr... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | NCT00859222 | Malignant Gliom... | LBH589 bevacizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Low Dose Naltrexone for Glioma Patients | NCT01303835 | Malignant Gliom... | LDN Placebo | 18 Years - | Duke University | |
| A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | NCT00080054 | Glioma Glioblastoma Astrocytoma Oligodendroglio... Brain Neoplasm | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma | NCT02858895 | Glioblastoma Grade IV Astroc... Glioblastoma Mu... Grade IV Glioma | MDNA55 | 18 Years - | Medicenna Therapeutics, Inc. | |
| Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors | NCT00075387 | Malignant Gliom... | Carboplatin Cyclophosphamid... Etoposide Phosp... Quality-of-Life... Sodium Thiosulf... | 18 Years - 75 Years | OHSU Knight Cancer Institute | |
| Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas | NCT04197492 | Malignant Gliom... | Hypofractionate... Anlotinib | 18 Years - 70 Years | Huashan Hospital | |
| Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma | NCT00979173 | Glioma | AC480 | 18 Years - | Duke University | |
| Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over | NCT02892708 | Malignant Gliom... | Surgery radiotherapy | 70 Years - | Assistance Publique - Hôpitaux de Paris | |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | NCT04541225 | Glioma Glioma, Maligna... Glioma, Mixed Glial Cell Tumo... Breast Cancer Breast Carcinom... Cancer of Breas... Cancer of the B... Breast Tumor Malignant Tumor... Advanced Breast... Advanced Breast... Metastatic Brea... Metastatic Brea... Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration-resi... Castration Resi... Glioblastoma Recurrent Gliob... | NUV-422 | 18 Years - | Nuvation Bio Inc. | |
| Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma | NCT05045027 | Glioma Malignant Gliom... Recurrent Gliom... Recurrent Malig... | Biospecimen Col... Diagnostic Imag... Magnetic Resona... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma | NCT01392209 | Brain Cancer MALIGNANT GLIOM... Glioblastoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Anaplastic Mixe... Malignant Gliom... | Bevacizumab & S... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme | NCT00458601 | Malignant Gliom... | CDX-110 with GM... Temozolomide | 18 Years - | Celldex Therapeutics | |
| Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme | NCT00919737 | Malignant Gliom... | NPC-08 | 18 Years - 64 Years | Nobelpharma | |
| Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery | NCT01798771 | Primary Maligna... Glioma Glioblastoma Metastasis | Interventional ... Control arm | 18 Years - | Johann Wolfgang Goethe University Hospital | |
| Molecular Characterization of Gliomas Using a Broad Next Generation Sequencing (NGS)Panel | NCT05486247 | Malignant Gliom... | 18 Years - | Hellenic Cooperative Oncology Group | ||
| Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma | NCT03615404 | Glioblastoma Malignant Gliom... Medulloblastoma... Pediatric Gliob... Pediatric Brain... Pediatric Brain... | CMV-DCs with GM... Td (tetanus tox... | 0 Years - 35 Years | Duke University | |
| Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM | NCT00612989 | Glioblastoma Gliosarcoma | Temodar and O6-... | 18 Years - | Duke University | |
| Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | NCT01266031 | Malignant Gliom... Recurrent Gliob... | vorinostat bevacizumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | NCT01248949 | Advanced Solid ... Advanced Recurr... | MEDI3617 Bevacizumab Paclitaxel Carboplatin | 18 Years - 99 Years | MedImmune LLC | |
| Early-Phase Safety of Proton Therapy Equipment | NCT02315989 | Malignant Gliom... Hepatocellular ... Head and Neck M... Prostate Cancer | proton therapy | 20 Years - 75 Years | Chang Gung Memorial Hospital | |
| A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | NCT00735436 | Malignant Gliom... Glioblastoma Mu... Gliosarcoma | Gliadel/Avastin... | 18 Years - | Duke University | |
| Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases | NCT00103038 | Central Nervous... Malignant Gliom... Metastatic Mali... | 3 Tesla Magneti... Dynamic Contras... Dynamic Suscept... Ferumoxytol Gadolinium MRI-Based Angio... | 18 Years - | OHSU Knight Cancer Institute | |
| AMG 102 and Avastin for Recurrent Malignant Glioma | NCT01113398 | Glioblastoma Mu... Gliosarcoma | AMG 102 Avastin | 18 Years - | Duke University | |
| Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG | NCT03033992 | Malignant Gliom... Ependymoma Diffuse Intrins... | Optune System (... Concurrent Optu... | 3 Years - 21 Years | Pediatric Brain Tumor Consortium | |
| A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | NCT01248949 | Advanced Solid ... Advanced Recurr... | MEDI3617 Bevacizumab Paclitaxel Carboplatin | 18 Years - 99 Years | MedImmune LLC | |
| Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma | NCT04771806 | Malignant Gliom... | Magnetic Resona... Neurocognitive ... Quality-of-Life... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma. | NCT00032903 | Malignant Gliom... | Gimatecan® (ST ... | 18 Years - | Sigma-Tau Research, Inc. | |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | NCT02684058 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Ipon... | Dabrafenib trametinib Carboplatin Vincristine | 12 Months - 17 Years | Novartis | |
| TRC105 for Recurrent Glioblastoma | NCT01778530 | Glioblastoma Mu... | TRC105 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Bevacizumab for Recurrent Malignant Glioma | NCT00271609 | Recurrent High-... Malignant Gliom... | Bevacizumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma | NCT01989052 | Malignant Gliom... | CTO Lomustine | 18 Years - | Duke University | |
| Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers | NCT04630379 | Glioblastoma Malignant Gliom... WHO Grade III G... | Palliative Ther... Quality-of-Life... Supportive Care Survey Administ... | 18 Years - | Mayo Clinic | |
| A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I) | NCT05540873 | Recurrent Malig... | YYB-103 | 19 Years - 74 Years | CellabMED | |
| Enhanced Detection in Glioma Excision | NCT04556929 | Glioma | Intra-operative... Intra-operative... Biopsies | 18 Years - | University of Oxford | |
| Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma | NCT04771806 | Malignant Gliom... | Magnetic Resona... Neurocognitive ... Quality-of-Life... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | NCT04238819 | Relapsed Solid ... Refractory Soli... | Abemaciclib Irinotecan Temozolomide Dinutuximab GM-CSF | - 21 Years | Eli Lilly and Company | |
| Fluorescence Guided Resection of Brain Tumors | NCT00870779 | Brain Tumors | 5-aminolevulini... | 21 Years - | Dartmouth-Hitchcock Medical Center | |
| Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy | NCT04650204 | Intractable Epi... Malignant Gliom... Seizure Disorde... WHO Grade 2 Gli... WHO Grade 3 Gli... | Anticonvulsant ... Perampanel Quality-of-Life... Questionnaire A... | 18 Years - | Mayo Clinic | |
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | NCT03220035 | Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor | Laboratory Biom... Vemurafenib | 12 Months - 21 Years | National Cancer Institute (NCI) | |
| Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | NCT00612430 | Glioblastoma Gliosarcoma | Bevacizumab and... | 18 Years - | Duke University | |
| Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas | NCT04197492 | Malignant Gliom... | Hypofractionate... Anlotinib | 18 Years - 70 Years | Huashan Hospital | |
| Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma | NCT01792505 | Malignant Gliom... | Dendritic Cell ... | 18 Years - | Cedars-Sinai Medical Center | |
| Image Guided Reirradiation of High-grade Glioma | NCT02025231 | Malignant Gliom... Glioblastoma | External beam r... | 18 Years - | Rigshospitalet, Denmark | |
| Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab | NCT02330562 | Malignant Gliom... Glioblastoma | MRZ BEV | 18 Years - | Celgene | |
| Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas | NCT03956706 | Glioblastoma Astrocytoma, Gr... Astrocytoma, Gr... Malignant Gliom... | Stereotactic Ra... | 18 Years - | Northwell Health | |
| Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide | NCT02991456 | Chemo-radiation... | Rolapitant Ondansetron | 18 Years - | Duke University | |
| Early-Phase Safety of Proton Therapy Equipment | NCT02315989 | Malignant Gliom... Hepatocellular ... Head and Neck M... Prostate Cancer | proton therapy | 20 Years - 75 Years | Chang Gung Memorial Hospital | |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | NCT02323880 | Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli... | Pharmacological... Selinexor | 12 Months - 21 Years | Children's Oncology Group | |
| Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma | NCT00024570 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Mixed Oligoastr... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | NCT03510208 | Malignant Brain... Malignant Gliom... | Near-Infrared F... Panitumumab Panitumumab-IRD... POINPOINT-IR900... | 18 Years - | Stanford University | |
| Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma | NCT01811992 | Malignant Gliom... Glioblastoma Mu... | Dose Escalation... | 18 Years - 75 Years | University of Michigan Rogel Cancer Center | |
| Bevacizumab Beyond Progression (BBP) | NCT01740258 | Malignant Gliom... Grade 4 Maligna... Glioblastoma Gliosarcoma | Radiation Thera... Temozolomide Bevacizumab | 18 Years - | Duke University | |
| Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | NCT00751270 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... | AdV-tk Valacyclovir | 18 Years - | Candel Therapeutics, Inc. | |
| Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields | NCT03501134 | Malignant Gliom... | NovoTTF | 18 Years - | Duke University | |
| Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | NCT00589875 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... High Grade Glio... | CAN-2409 Valacyclovir Temozolomide Radiation thera... | 18 Years - | Candel Therapeutics, Inc. | |
| Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | NCT03718767 | Glioma Glioblastoma High Grage Glio... Low Grade Gliom... Malignant Gliom... | Nivolumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| CARv3-TEAM-E T Cells in Glioblastoma | NCT05660369 | Glioblastoma Malignant Gliom... Recurrent Gliob... Recurrent Gliom... | CARv3-TEAM-E T ... | 18 Years - | Massachusetts General Hospital | |
| Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients | NCT00024557 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Mixed Oligoastr... Malignant Astro... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma | NCT03615404 | Glioblastoma Malignant Gliom... Medulloblastoma... Pediatric Gliob... Pediatric Brain... Pediatric Brain... | CMV-DCs with GM... Td (tetanus tox... | 0 Years - 35 Years | Duke University | |
| Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma | NCT02507583 | Malignant Gliom... Neoplasms | IGF-1R/AS ODN; ... | 18 Years - | Thomas Jefferson University | |
| AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma | NCT03893903 | Malignant Gliom... | IDH1R132H pepti... Avelumab | 18 Years - | German Cancer Research Center | |
| Lacosamide in Preventing Seizures in Participants With Malignant Glioma | NCT01432171 | Malignant Gliom... | Lacosamide Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | NCT02794883 | Malignant Gliom... Recurrent Gliob... | Durvalumab Laboratory Biom... Surgical Proced... Tremelimumab | 18 Years - | Northwestern University | |
| A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | NCT02924038 | Glioma Malignant Gliom... Astrocytoma, Gr... Oligodendroglio... Glioma, Astrocy... Oligoastrocytom... | IMA950 poly-ICLC Varlilumab | 18 Years - | University of California, San Francisco | |
| Characterization of Serial Magnetic Resonance Spectroscopy Imaging in Patients With Malignant Glioma Undergoing Radiotherapy | NCT00125697 | Malignant Gliom... | 3T MRI Scanning | 18 Years - | AHS Cancer Control Alberta | |
| Phase I/II Cabazitaxel for Recurrent Malignant Glioma | NCT01740570 | Brain Cancer | Cabazitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients | NCT02575261 | EphA2 Positive ... CAR-T Cell Immu... | CAR-T cell immu... | 18 Years - 80 Years | Fuda Cancer Hospital, Guangzhou | |
| Low Dose Naltrexone for Glioma Patients | NCT01303835 | Malignant Gliom... | LDN Placebo | 18 Years - | Duke University | |
| 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy | NCT03778294 | Glioblastoma Malignant Gliom... | Computed Tomogr... Fluorodopa F 18 Magnetic Resona... Positron Emissi... Proton Beam Rad... Quality-of-Life... Questionnaire A... Temozolomide | 65 Years - | Mayo Clinic | |
| Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure | NCT01954030 | Malignant Gliom... | CTO and Bevaciz... CTO alone | 18 Years - | Duke University | |
| Early Palliative Care Intervention in Malignant Glioma | NCT03471546 | Malignant Gliom... | Palliative Care | 18 Years - | Duke University | |
| Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | NCT01110876 | Brain Cancer Glioblastoma Mu... | Vorinostat Erlotinib Temozolomide | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
